Reported by FiercePharma and based on a report by Stat News (behind paywall).
Taking a cue from AbbVie’s playbook, Teva is the latest drugmaker to walk away from the Pharmaceutical Research and Manufacturers of America (PhRMA).
“Teva has decided not to renew its membership with PhRMA in 2023,” Brian Newell, spokesperson for the influential lobbying group, said over email. Teva also confirmed its departure in a statement provided to Fierce Pharma.
As with AbbVie in December, Teva’s rationale wasn’t immediately clear. Teva is the leading producer of generic drugs worldwide, but the company also markets branded medicines such as migraine prevention med Ajovy and Austedo for tardive dyskinesia.
“We annually review effectiveness and value of engagements, consultants and memberships to ensure our investments are properly seated,” a Teva spokesperson explained over email. “We continue to remain engaged—in DC and around the world—on the issues important to our company and to the millions of patients who rely on our products.”
I recall there was a lot of discussion a while back when PhRMA decided to be focused on industry advocacy and be less involved in science-based regulatory guidance interactions. The article provides a bit on AbbVie and Teva's rational for leaving the organization and the focus for PhRMA's activities from this year's Chair.
Have you heard anything on other company's activity with PhRMA?
No comments:
Post a Comment